Precipio Quantitative BCR-ABL 2.0 Panel

Precipio has launched its Quantitative BCR-ABL 2.0 panel for confirming a chronic myeloid leukemia (CML) diagnosis. According to the New Haven, Connecticut-based firm, CML patients have cells containing the BCR-ABL1 gene, which creates a hybrid protein resulting in uncontrolled cell division and genomic instability. The presence of the gene confirms CML diagnosis and can be used to monitor patients and their response to various therapies. The test provides quantitative coverage of four clinically relevant breakpoints, p.190, p.210, p.203, and p.230, and the panel comes with automated analysis software, Precipio said.